Mfg Part Number
Ab03226-10.0

Vector Labs Ab03226-10.0 Anti-ADAMTS5 [7B4], Human IgG1, kappa (200 μg)

Quick Overview
Vector Labs Ab03226-10.0 Anti-ADAMTS5 [7B4], Human IgG1, kappa (200 μg)
$517.40
Order will ship within 1-3 business days
Add to Wish List
Product Class:Purified
Clone ID:7B4
Synonyms:A disintegrin and metalloproteinase with thrombospondin motifs 5; Aggrecanase; ADAM-TS 5; ADAM-TS5; ADAMTS-5; A disintegrin and metalloproteinase with thrombospondin motifs 11; ADAM-TS 11; ADAMTS-11; ADMP-2; Aggrecanase-2; 7B4.1E11
Amount:200 μg
Application Codes Clone:Crystallography; IHC; in vivo; inhibition
Shipping Temperature:Wet Ice
Buffer Composition:PBS with 0.02% Proclin 300.
Original Format:IgG1
Storage Temperature:Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format for improved compatibility with existing reagents assays and techniques.
Specificity Statement:The antibody is specific for ADAMTS5 and it recognises an epitope within the catalytic and disintegrin domains (amino acids 262-576). ADAMTS-5 is a protease involved in cartilage degradation in human OA patients.
Application Notes:The antibody was characterized for binding affinity, species cross-reactivity and domain specificity. The antibody showed inhibitory potency (IC50) of 41.26 nM and humanization improved potency to 11.12 nM. The affinity of the original antibody and humanized version was measured, Kd= 0.280 nM and 0.205 nM respectively. Epitope mapping and selective binding to purified recombinant ADAMS5 were profiled by DELFIA. Selective binding of the antibody is demonstrated by immunocytochemistry using ADAMTS-5 and CHO cells. The antibody inhibited aggrecanolysis from human OA cartilage explants. The ability of the antibody to engage its target in vivo was assessed using labeled antibody in a preclinical OA model and whole body imaging was used to monitor biodistribution and cartilage penetration. The antibody treatment suppressed joint disease severity and mechanical allodynia. The crystal structure of the Fab fragment was determined (Larkin et al., 2015; PMID: 25800415).
More Information
Brand Vector Labs
UNSPSC 12161500